Q1 2025 13F Holders as of 3/31/2025
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
236M
-
Number of holders
-
142
-
Total 13F shares, excl. options
-
95.2M
-
Shares change
-
+33M
-
Total reported value, excl. options
-
$183M
-
Value change
-
+$63.4M
-
Put/Call ratio
-
3.24
-
Number of buys
-
91
-
Number of sells
-
-29
-
Price
-
$1.92
Significant Holders of Akebia Therapeutics, Inc. - Common Stock (AKBA) as of Q1 2025
154 filings reported holding AKBA - Akebia Therapeutics, Inc. - Common Stock as of Q1 2025.
Akebia Therapeutics, Inc. - Common Stock (AKBA) has 142 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 95.2M shares
of 236M outstanding shares and own 40.32% of the company stock.
Largest 10 shareholders include BlackRock, Inc. (15.3M shares), VANGUARD GROUP INC (12.7M shares), STATE STREET CORP (6.81M shares), GEODE CAPITAL MANAGEMENT, LLC (5.03M shares), GREAT POINT PARTNERS LLC (4.97M shares), RENAISSANCE TECHNOLOGIES LLC (4.01M shares), CITADEL ADVISORS LLC (3.65M shares), AIGH Capital Management LLC (2.93M shares), GOLDMAN SACHS GROUP INC (2.72M shares), and MORGAN STANLEY (2.68M shares).
This table shows the top 142 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.